 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || MEDI7247 / AstraZeneca
P1 data, Journal: ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. (Pubmed Central) - Apr 29, 2024
P1
Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).
- | MEDI7247 / AstraZeneca
Preclinical, Journal: Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. (Pubmed Central) - Jul 20, 2023
Preclinical biodistribution analyses of [Zr]Zr-Df-MEDI7247 and [Zr]Zr-Df-MEDI7519 showed the biodistribution pattern of anti-ASCT2 ADC MEDI7247 was similar to parental MEDI7519, and both antibodies showed specific tumor uptake compared to an isotype control ADC. This study highlights an important role nuclear medicine imaging techniques can play in early preclinical assessment of drug specificity as part of the drug development pipeline.
- ||| MEDI7247 / AstraZeneca
Trial completion: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Feb 28, 2020
P1, N=67, Completed, Sponsor: MedImmune LLC
This study highlights an important role nuclear medicine imaging techniques can play in early preclinical assessment of drug specificity as part of the drug development pipeline. Active, not recruiting --> Completed
- ||| oleclumab (MEDI9447) / AstraZeneca, AZD4635 / AstraZeneca, MEDI7247 / AstraZeneca
$AZN discontinuations: MEDI7247 (anti-ASCT2 ADC) & oleclumab+AZD4635 combo (CD73+A2A inh, relevant to $CRVS ) (Twitter) - Feb 14, 2020
- || MEDI7247 / AstraZeneca
Trial completion, MSi-H Biomarker, Metastases: A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 29, 2019
P1, N=8, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | MEDI7247 / AstraZeneca
Trial completion date, Trial primary completion date, MSi-H Biomarker, Metastases: A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 4, 2019
P1, N=8, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Trial completion date: Mar 2022 --> Dec 2019 | Trial primary completion date: Mar 2022 --> Dec 2019
- | MEDI7247 / AstraZeneca
Enrollment closed, Enrollment change, MSi-H Biomarker, Metastases: A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 3, 2019
P1, N=8, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Mar 2022 --> Dec 2019 | Trial primary completion date: Mar 2022 --> Dec 2019 Recruiting --> Active, not recruiting | N=336 --> 8
- | MEDI7247 / AstraZeneca
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Aug 28, 2019
P1, N=67, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=336 --> 8 Recruiting --> Active, not recruiting | N=408 --> 67 | Trial completion date: Jul 2021 --> Feb 2020 | Trial primary completion date: Jul 2021 --> Feb 2020
- ||| MEDI7247 / AstraZeneca
New P1 trial, MSi-H Biomarker, Metastases: A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 21, 2019
P1, N=336, Recruiting, Sponsor: MedImmune LLC
- || MEDI7247 / AstraZeneca
Enrollment change: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Jan 4, 2019
P1, N=408, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=408 --> 67 | Trial completion date: Jul 2021 --> Feb 2020 | Trial primary completion date: Jul 2021 --> Feb 2020 N=228 --> 408
- | MEDI7247 / AstraZeneca
Trial completion date, Trial primary completion date: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Sep 24, 2018
P1, N=228, Recruiting, Sponsor: MedImmune LLC
N=228 --> 408 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- ||| MEDI7247 / AstraZeneca
New P1 trial: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Apr 10, 2017
P1, N=228, Recruiting, Sponsor: MedImmune LLC